CAESAREA, Israel–(BUSINESS WIRE)–Itamar-Medical, the
leading provider of diagnostic devices for cardiovascular disease and sleep
apnea based on its proprietary PAT® signal technology, will unveil its
cardiovascular healthcare assessment platform, EndoPAT-MF, at the upcoming American College
of Cardiology Conference in Chicago.
Multi-function EndoPAT-MF now features 5 major diagnostic
tools in a single system. In addition to providing (1) the only
FDA-cleared, non-invasive measure of Endothelial Function, now also features
(2) Augmentation Index (measuring arterial stiffness) and (3) Heart
Rate Variability (offering a window onto the Autonomic Nervous System), as well
as (4) leading Risk Score calculators (Framingham, Reynolds and SCORE) and
(5) an integrated web-based platform, EndoCloud, to provide seamless and
efficient patient diagnosis information transfer in a timely manner.
“The fact that heart disease starts in the arteries and
blood vessels makes EndoPAT a critical tool for early detection and continued
physiological assessment of the health of the vascular system. More than half
of all sudden cardiac deaths occur with no previous symptoms and cardiovascular
disease continues to be the leading health risk in the U.S. Our
continued enhancements to EndoPAT offer a significant value in this
next-generation tool set for early detection and analysis for patient, payer,
provider, and physician,” said Marvin Slosman, US President Itamar-Medical Inc.
Multi-function EndoPAT-MF will be available upon meeting the
regulatory requirements in each of the international geographies. The
integrated platform will enable all users to benefit from convenience and cost
savings by performing the diagnostic tasks of several devices on a single,
unified platform.
“Our EndoPAT technology provides easy access for these next
generation diagnostic modalities, thus adding tremendous value to what is
rapidly becoming the standard of care in detection of cardiovascular disease,”
said Efrat Litman, Vice President R&D.
